{"id":567912,"date":"2021-10-07T19:52:01","date_gmt":"2021-10-07T19:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=567912"},"modified":"2021-10-07T19:52:01","modified_gmt":"2021-10-07T19:52:01","slug":"pompe-disease-pipeline-industry-analysis-drugs-pipeline-treatment-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pompe-disease-pipeline-industry-analysis-drugs-pipeline-treatment-and-key-companies-by-delveinsight_567912.html","title":{"rendered":"Pompe Disease Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1633605514.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pompe Disease Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1633605514.jpeg\" alt=\"Pompe Disease Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Pompe Disease Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<strong>&lsquo;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>Pompe Disease Pipeline Insights<\/strong><\/a><strong>&rsquo;<\/strong>&nbsp;report offers comprehensive coverage of the emerging Pompe Disease therapeutics landscape in different stages of clinical development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.<\/p>\n<p style=\"text-align: justify;\">The Pompe Disease Pipeline report provides a complete outlook of the clinical trials, colloborations happening in the domain, recent breakthroughs and growth prospects across the Pompe Disease domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key highlights from the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Pompe Disease Pipeline<\/a>&nbsp;report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Pompe Disease Pipeline report offers a rich analysis of&nbsp;<strong>17+&nbsp;<\/strong>key players and&nbsp;<strong>17+&nbsp;<\/strong>key therapies.<\/li>\n<li>Pompe Disease pipeline comprises therapies in different stages of the clinical phase such as include<strong>&nbsp;Cipaglucosidase alfa, SPK-3006, ACTUS 101, AT845, RP A501, AOC-Pompe disease, AVR RD 03, GYS1 Program, ETV-GAA,&nbsp;<\/strong>and many others expected to enter the Pompe Disease market in the coming years.<\/li>\n<li>Key companies strengthening the Pompe Disease Pipeline are&nbsp;<strong>Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Rocket Pharmaceuticals, Avidity Biosciences, AVROBIO, Maze Therapeutics, Denali Therapeutics&nbsp;<\/strong>among others.<\/li>\n<li>In May 2021, Amicus Therapeutics announced the completion of a successful Type B Pre-Biologics License Application (BLA) meeting with the US Food and Drug Administration (FDA) for AT-GAA (cipaglucosidase alfa co-administered with miglustat), for the treatment of Pompe disease.<\/li>\n<li>In March 2021, Maze Therapeutics revealed its first three lead therapeutic candidates in the company&rsquo;s wholly owned pipeline. One of the candidates includes an oral therapy targeting GYS1 for the treatment of Pompe disease, enabled by Maze&rsquo;s COMPASS platform. The company expects to start clinical trials in the first half of 2022.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Report@&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pompe-disease-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr%20\">https:\/\/www.delveinsight.com\/sample-request\/pompe-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pompe Disease: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Pompe Disease is a rare genetic disease that is a result of a build-up of a complex sugar, glycogen in the cells of the body. It exhibits variable rates of progression and different ages of onset. The cause of the disease is a deficiency of an enzyme called acid alfa glucosidase (GAA), which breaks downs complex sugars in the body.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pompe Disease Pipeline Drugs<\/strong><\/p>\n<table style=\"width: 605px;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"top\">\n<p><strong>Drug<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p><strong>Company<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p><strong>Phase<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p><strong>MoA<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p><strong>RoA<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>Cipaglucosidase alfa<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Amicus Therapeutics<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Preregistration<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Alpha-glucosidase replacements<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>SPK-3006<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Spark Therapeutics<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase I\/II<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Alpha-glucosidase expression stimulants<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>AT845<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Audentes Therapeutics<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase I\/II<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Gene transference<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>ACTUS 101<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Asklepios Biopharmaceutical<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase I\/II<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Gene transference<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Intravenous<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>RP A501<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Rocket Pharmaceuticals<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Phase I<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Gene transference<\/p>\n<\/td>\n<td valign=\"top\">\n<p>NA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>AVR-RD-03<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>AVROBIO<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Preclinical<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Alpha-glucosidase stimulants<\/p>\n<\/td>\n<td valign=\"top\">\n<p>NA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p><strong>AOC-Pompe disease<\/strong><\/p>\n<\/td>\n<td valign=\"top\">\n<p>Avidity Biosciences<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Discovery<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Glycogen synthase kinase modulators<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Parenteral<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Report@&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pompe-disease-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr%20\">https:\/\/www.delveinsight.com\/sample-request\/pompe-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Pompe Disease Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The Pompe Disease Pipeline report lays down complete insights into active Pompe Disease pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.<\/p>\n<p style=\"text-align: justify;\"><strong>By Product Type<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Mono<\/li>\n<li>Combination<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Stage<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Discovery<\/li>\n<li>Pre-clinical<\/li>\n<li>IND<\/li>\n<li>Phase I<\/li>\n<li>Phase II<\/li>\n<li>Phase III<\/li>\n<li>Pre-registration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Molecule Type<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Gene therapies<\/li>\n<li>Recombinant fusion proteins<\/li>\n<li>Small interfering RNA<\/li>\n<li>Cell therapies<\/li>\n<li>Monoclonal antibodies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Route of Administration<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intravenous<\/li>\n<li>Parenteral<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Mechanism of Action<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Alpha-glucosidase replacements<\/li>\n<li>Glycogen synthase kinase modulators<\/li>\n<li>RNA interference<\/li>\n<li>Gene transference<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>By Targets<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Alpha-glucosidase<\/li>\n<li>Gene replacement<\/li>\n<li>Glycogen synthase kinase<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Report@&nbsp;https:\/\/www.delveinsight.com\/sample-request\/pompe-disease-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the&nbsp;Pompe Disease Pipeline&nbsp;Report<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Coverage<\/strong>: Global <strong>Key Players<\/strong>: Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Rocket Pharmaceuticals, Abeona Therapeutics, AVROBIO, Maze Therapeutic, Denali Therapeutics, Immusoft, Avidity Biosciences, and others. <strong>Key Pompe Disease Pipeline Therapies<\/strong>: Cipaglucosidase alfa, SPK-3006, ACTUS 101, AT845, RP A501, AIM vectors, AVR RD 03, GYS1 Program, ETV-GAA, Research programme: glycogen storage disease type II therapy, AOC-Pompe disease, and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table style=\"width: 500px;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"top\">\n<p>1<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>2<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Disease Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>3<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Pipeline Outlook<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>4<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Comparative Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>5<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Therapeutic Products in Clinical Stage<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>6<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Late Stage Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>7<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>8<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>9<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Therapeutic Products in Non-clinical Stage<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>10<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Preclinical and Discovery Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>11<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>12<\/p>\n<\/td>\n<td valign=\"top\">\n<p>In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>13<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Collaboration Deals<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>14<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Therapeutics Pipeline Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>15<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Inactive Pompe Disease Pipeline Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>16<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>17<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease- Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>18<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>19<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Pompe Disease- Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>20<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>21<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Report Methodology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>22<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Consulting Services<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>23<\/p>\n<\/td>\n<td valign=\"top\">\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"top\">\n<p>24<\/p>\n<\/td>\n<td valign=\"top\">\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Delveinsight:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/p>\n<p style=\"text-align: justify;\">Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform&nbsp;<strong>PharmDelve<\/strong>.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pompe-disease-pipeline-industry-analysis-drugs-pipeline-treatment-and-key-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pompe-disease-pipeline-industry-analysis-drugs-pipeline-treatment-and-key-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pompe Disease Pipeline DelveInsight&rsquo;s&nbsp;&lsquo;Pompe Disease Pipeline Insights&rsquo;&nbsp;report offers comprehensive coverage of the emerging Pompe Disease therapeutics landscape in different stages of clinical development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents. The Pompe Disease &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pompe-disease-pipeline-industry-analysis-drugs-pipeline-treatment-and-key-companies-by-delveinsight_567912.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-567912","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/567912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=567912"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/567912\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=567912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=567912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=567912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}